Core Insights - Yatsen E-commerce (YSG.US) reported Q2 2025 revenue of 1.09 billion yuan, a 36.8% increase year-over-year, exceeding previous guidance [1] - The skincare segment grew by 78.7% to 580 million yuan, accounting for 53.5% of total revenue, marking a historical high for quarterly revenue contribution [1] - The company achieved a gross profit increase of 39.5%, with a gross margin rising to 78.3%, and Non-GAAP net profit turning positive at 11.5 million yuan [1] Financial Performance - Q2 2025 revenue reached 1.09 billion yuan, up 36.8% from the same period last year [1] - Gross profit increased by 39.5%, with a gross margin of 78.3% [1] - Non-GAAP net profit was 11.5 million yuan, indicating sustained profitability over three consecutive quarters [1] Research and Development - R&D expenses for Q2 2025 were 36.12 million yuan, representing 3.3% of total revenue, maintaining over 3% for three consecutive years [1] - The company’s Shanghai Innovation R&D Center received national CNAS certification, enhancing its competitive edge [2] - The launch of the "Yatsen Group Beauty Innovation White Paper" showcases the company's commitment to R&D and its global beauty technology advancements [2] Strategic Vision - The company aims to be a "world-class beauty innovation pioneer," focusing on a "R&D-driven" growth model to convert scientific achievements into market-leading products [2] - The CEO emphasized the importance of high-quality products and brand asset consolidation for sustained growth [2] - Q3 2025 revenue is projected to be between 780 million and 880 million yuan, reflecting a year-over-year growth of approximately 15% to 30% [2]

智通财经APP获悉，8月21日，逸仙电商（YSG.US）发布2025年第二季度业绩报告。公告显示，公司二 季度实现营收10.9亿元，较去年同期增长36.8%，超出此前业绩指引。期内，凭借科技力加持，逸仙电 商多品牌齐发力，产品力不断提升，护肤业务与彩妆业务双双增长，其中护肤业务同比增长78.7%至5.8 亿元，占总营收的比例提升至53.5%，护肤单季度营收贡献率创历史新高。 得益于营收结构持续优化，公司提质增效成果显著。根据财报，二季度公司毛利润同比增长39.5%，毛 利率增至78.3%，Non-GAAP净利润进一步转正至1150万元。至此，逸仙电商已实现连续3个季度营收正 向增长的同时，Non-GAAP层面持续盈利。 报告期内，逸仙电商持续加码研发投入。财报显示，2025年第二季度的研发费用达3612万，研发费用占 比3.3%，实现连续三年研发费用占比达3%以上，研发投入力度持续稳居全球第一梯队。高研发投入 下，公司研发创新实力持续跃升。 期内，逸仙全球创新研发中心上海分析实验室获国家级CNAS认证，完美日记第三代仿生膜科技 Biotec™重磅升级，独家原料再获国家药监局备案，为旗下产品竞争力提升注入新动能 ...